Company Profile
Cardiff Oncology Stock Price, News & Analysis
- Ticker:
- CRDF
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.96 USD (+0.57%)
Close
Last updated: August 6, 2026
103M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, CRDF closed up 0.57% at $0.9604. No new same-company headline was identified in the current news window.
Company overview
Business overview
Cardiff Oncology is an oncology company focused on precision cancer therapy and cell-cycle biology. Its development strategy is centered on targeted treatment combinations for solid tumors.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Cardiff sits in specialty oncology biotechnology.
Business Model Characteristics
The business depends on clinical data, pathway validation, and the ability to create a differentiated oncology franchise.
Position Within the Biotechnology Landscape
Cardiff is a small-cap oncology catalyst name whose stock moves on early clinical readouts.
Future catalysts
Cardiff Oncology’s catalysts are onvansertib and the KRAS-driven oncology program, especially any new combination or clinical data that keep the story alive. The company remains highly dependent on proof of differentiation.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Cardiff Oncology (CRDF)?
Cardiff Oncology (CRDF) most recently closed at 0.96 USD, a +0.57% move versus the previous session.
What is the market cap of Cardiff Oncology (CRDF)?
Cardiff Oncology currently has a market capitalization of 103M USD on BioPharmSignal.
What does Cardiff Oncology do?
Cardiff Oncology is an oncology company focused on precision cancer therapy and cell-cycle biology. Its development strategy is centered on targeted treatment combinations for solid tumors.
On which exchange is CRDF stock listed?
Cardiff Oncology (CRDF) is associated with NASDAQ, United States, Biopharma.
What is onvansertib?
Cardiff Oncology’s catalysts are onvansertib and the KRAS-driven oncology program, especially any new combination or clinical data that keep the story alive.
Which conditions is Cardiff Oncology targeting with onvansertib?
Cardiff Oncology is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Cardiff Oncology describe recent progress with onvansertib?
Cardiff Oncology’s catalysts are onvansertib and the KRAS-driven oncology program, especially any new combination or clinical data that keep the story alive.
What is Cardiff?
Cardiff Oncology is an oncology company focused on precision cancer therapy and cell-cycle biology.